[HTML][HTML] Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD
MJ Mäkelä, V Backer, M Hedegaard, K Larsson - Respiratory medicine, 2013 - Elsevier
Suboptimal adherence to pharmacological treatment of asthma and chronic obstructive
pulmonary disease (COPD) has adverse effects on disease control and treatment costs. The …
pulmonary disease (COPD) has adverse effects on disease control and treatment costs. The …
Treatment strategies for asthma: reshaping the concept of asthma management
A Papi, F Blasi, GW Canonica, L Morandi… - Allergy, Asthma & …, 2020 - Springer
Asthma is a common chronic disease characterized by episodic or persistent respiratory
symptoms and airflow limitation. Asthma treatment is based on a stepwise and control-based …
symptoms and airflow limitation. Asthma treatment is based on a stepwise and control-based …
Inhaled combined budesonide–formoterol as needed in mild asthma
Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a
fast-acting β2-agonist may be an alternative to conventional treatment strategies. Methods …
fast-acting β2-agonist may be an alternative to conventional treatment strategies. Methods …
As-needed budesonide–formoterol versus maintenance budesonide in mild asthma
Background Patients with mild asthma often rely on inhaled short-acting β2-agonists for
symptom relief and have poor adherence to maintenance therapy. Another approach might …
symptom relief and have poor adherence to maintenance therapy. Another approach might …
[HTML][HTML] Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey
Background: Asthma is one of the most common chronic diseases in the world, and previous
studies have reported low levels of control. Recent developments in the availability and use …
studies have reported low levels of control. Recent developments in the availability and use …
Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma
Rationale: IL-17 signaling has been implicated in development and persistence of asthma.
Cytokine-targeted strategies blocking IL-17 receptor signaling may be beneficial in asthma …
Cytokine-targeted strategies blocking IL-17 receptor signaling may be beneficial in asthma …
Functions of T cells in asthma: more than just TH2 cells
Asthma has been considered a T helper 2 (TH2) cell-associated inflammatory disease, and
TH2-type cytokines, such as interleukin-4 (IL-4), IL-5 and IL-13, are thought to drive the …
TH2-type cytokines, such as interleukin-4 (IL-4), IL-5 and IL-13, are thought to drive the …
2020 NAEPP guidelines update and GINA 2021—asthma care differences, overlap, and challenges
BE Chipps, KR Murphy, J Oppenheimer - The Journal of Allergy and …, 2022 - Elsevier
The 2020 National Asthma Education and Prevention Program Coordinating Committee
Expert Panel Working Group (NAEPP [2020 Focused Asthma Update]) guidelines and the …
Expert Panel Working Group (NAEPP [2020 Focused Asthma Update]) guidelines and the …
Asthma: pathogenesis and novel drugs for treatment
JT Olin, ME Wechsler - Bmj, 2014 - bmj.com
Asthma affects almost 20 million people in the United States and more than 300 million
people worldwide. Of these, 10-15% have severe asthma, which is refractory to commonly …
people worldwide. Of these, 10-15% have severe asthma, which is refractory to commonly …
SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
Introduction Globally, individuals with asthma tend to overrely on short-acting β 2-agonists
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …